Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation
Files
(Published version)
Date
2022
Authors
Adnan Awad, S.
Brück, O.
Shanmuganathan, N.
Jarvinen, T.
Lähteenmäki, H.
Klievink, J.
Ibrahim, H.
Kytölä, S.
Koskenvesa, P.
Hughes, T.P.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Blood Cancer Journal, 2022; 12(4, article no. 69)
Statement of Responsibility
Conference Name
Abstract
School/Discipline
Dissertation Note
Provenance
Description
Data source: Supplementary information, https://doi.org/10.1038/s41408-022-00667-9
Access Status
Rights
Copyright 2022 The Author(s). This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. (http://creativecommons.org/licenses/by/4.0/)